Key facts
- This page summarizes David Arkowitz's Form 4 filing for iBio, Inc. (IBIO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 13 Jan 2025, 16:32.
David Arkowitz - 10 Jan 2025 Form 4 Insider Report for iBio, Inc. (IBIO)
- Reporting relationship
- Director
- Issuer ticker
- IBIO
- Reported as of
- 10 Jan 2025
- Net transaction value
- +$49,999
- SEC form
- 4
- Accepted by SEC
- 13 Jan 2025, 16:32:54 UTC
- Prior SEC filing
- 25 Nov 2024
- Next SEC filing
- 25 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marc Banjak, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Arkowitz filed Form 4 for iBio, Inc. (IBIO) on 13 Jan 2025.
Change
- Previous filing in this sequence was filed on 25 Nov 2024.
- Current net transaction value: +$49,999.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IBIO
transaction
Common Stock
Purchase
- Transaction value
- $49,999
- Shares
- +18,382
- Change %
- Price
- $2.72
- Shares after
- 18,382
- Date
- 10 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025.